title: Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules.
abstract: OBJECTIVE
  Treatment of sensorineural hearing loss could be advanced using novel drug carriers such as hyperbranched polylysine (HBPL) or lipid nanocapsules (LNCs). This study examined HBPL and LNCs for their cellular uptake and possible toxicity in vitro and in vivo as the first step in developing novel nanosized multifunctional carriers.
  
  
  METHODS
  Having incubated HBPL and LNCs with fibroblasts, nanoparticle uptake and cell viability were determined by confocal laser scanning microscopy, fluorescence measurements and neutral red staining. In vivo, electrophysiology, confocal laser scanning microscopy and cytocochleograms were performed for nanoparticle detection and also toxicity studies after intracochlear application.
  
  
  RESULTS
  Both nanoparticles were detectable in the fibroblasts' cytoplasm without causing cytotoxic effects. After in vivo application they were visualized in cochlear cells, which did not lead to a change in hearing threshold or loss of hair cells. Biocompatibility and traceability were demonstrated for HBPL and LNCs. Thus, they comply with the basic requirements for drug carriers for potential application in the inner ear.
authors: Department of Otolaryngology, Medical University Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. scheper.verena@mh-hannover.de
authors: Verena
authors: V
authors: Scheper
authors: Melanie
authors: M
authors: Wolf
authors: Markus
authors: M
authors: Scholl
authors: Zuzana
authors: Z
authors: Kadlecova
authors: Thomas
authors: T
authors: Perrier
authors: Harm-Anton
authors: HA
authors: Klok
authors: Patrick
authors: P
authors: Saulnier
authors: Thomas
authors: T
authors: Lenarz
authors: Timo
authors: T
authors: Stöver
mesh_terms: D000818:Animals; D003051:Cochlea / Q000503:physiopathology / Q000601:surgery; D004337:Drug Carriers / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D007758:Ear, Inner / Q000503:physiopathology*; D016650:Fluorescein-5-isothiocyanate / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D006168:Guinea Pigs; D006198:Hair Cells, Auditory / Q000187:drug effects; D006319:Hearing Loss, Sensorineural / Q000503:physiopathology / Q000628:therapy; D007211:Indoles / Q000378:metabolism; D008055:Lipids / Q000009:adverse effects / Q000627:therapeutic use*; D053769:Nanocapsules / Q000009:adverse effects / Q000737:chemistry* / Q000627:therapeutic use; D010590:Phalloidine / Q000378:metabolism; D011107:Polylysine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D012235:Rhodamines / Q000378:metabolism
chemical_list: D004337:Drug Carriers; D005456:Fluorescent Dyes; D007211:Indoles; D008055:Lipids; D053769:Nanocapsules; D012235:Rhodamines; D010590:Phalloidine; D011107:Polylysine; C007293:DAPI; D016650:Fluorescein-5-isothiocyanate